Hellman & Friedman Capital Partners X (Parallel), L.P. sold $1.2B of MDLN (indirect holdings)

Hellman & Friedman Capital Partners X (Parallel), L.P. sold 31,868,237 indirectly-held shares of Medline Inc. (MDLN) at $36.54 ($1.16B total) across 4 trades on 2026-05-28. Filed jointly with HFCP X (Parallel-A), L.P. (10% owner), Mend Partners II, L.P. (10% owner), Mend Investment Holdings I, L.P. (10% owner), Hellman & Friedman Investors X, L.P. (10% owner), Mend Partners GP, LLC (10% owner), Mend Investment Holdings GP, LLC (10% owner), Hellman & Friedman Capital Partners X, L.P. (10% owner) and H&F Corporate Investors X, Ltd. (10% owner).

Original reporting
SEC EDGAR · Hellman & Friedman Capital Partners X (Parallel), L.P., HFCP X (Parallel-A), L.P., Mend Partners II, L.P., Mend Investment Holdings I, L.P., Hellman & Friedman Investors X, L.P., Mend Partners GP, LLC, Mend Investment Holdings GP, LLC, Hellman & Friedman Capital Partners X, L.P., H&F Corporate Investors X, Ltd.
Published Jun 1, 2026, 10:16 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 28, 2026, 3:47 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$MDLN
Bearish
high confidence
Mentioned
$MDLN
Relevance
9/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MDLNBearishMed
01

Why it matters

The disclosed insider sell is a primary source filing, indicating a material reduction in ownership and likely negative market reaction.

02

Market read

First‑report insider sale of over $1 B; traders may consider short‑term downside risk.

03

What to watch

Potential tax‑loss harvesting or liquidity needs of the selling entities.

Relevance 9/10Novelty 8/10Timing: post‑market today

Background

Hellman & Friedman Capital Partners X (Parallel) and affiliated entities collectively own 10% of Medline Inc. and filed a Form 4 reporting a multi‑trade sale.

Company-level read

Ticker impact

$MDLNBearishHigh confidence
Context

Form 4 disclosed a $1.16 B open‑market sale of 31.9 M shares by a 10% owner, reducing holdings to 6.5 M shares.

Expected impact

likely downward pressure as the market prices in the sizable insider sale

Evidence & confidence

The sale represents a material portion of float and is the first public disclosure of this transaction.

Market effects

May prompt scrutiny of other large shareholders in the medical supplies sector.

Limited to U.S. investors; no broader regional effect.

Low; impact confined to MDLN and its immediate peers.

Counterpoint

The sale could be a portfolio rebalancing unrelated to company fundamentals.

Key entities

  • Medline Inc.

    Medical supplies manufacturer (ticker MDLN).

  • Hellman & Friedman Capital Partners X (Parallel), L.P.

    Private equity affiliate holding a 10% stake in Medline.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$MDLNMed

Medline stock falls as shareholders price secondary offering

Medline Inc (MDLN) shares fell 3.5% premarket after selling stockholders, including affiliates of Blackstone and Carlyle, priced a 60M share secondary offering at $35.50 per share. Medline will repurchase $200M of stock from these sellers. The offering is expected to close November 23, 2026, with underwriters having a 30-day option for additional shares. Medline is not selling shares and will not receive proceeds.

$MDLNHighAI 9/10

Why is Medline stock sliding today?

Medline (MDLN) stock fell 3.3% in pre-market trading after a consortium of shareholders priced a secondary offering of 60 million shares at $35.50 each, totaling $2.13 billion. The offering's below-market price and a securities fraud investigation by Bleichmar Fonti & Auld LLP contributed to the decline. Medline is not selling shares and will not receive proceeds. The stock has dropped significantly from its 52-week high of $50.88.